| __timestamp | Summit Therapeutics Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 6795238 | 91733000 |
| Thursday, January 1, 2015 | 7454247 | 87644000 |
| Friday, January 1, 2016 | 10345862 | 92365000 |
| Sunday, January 1, 2017 | 16984203 | 85656000 |
| Monday, January 1, 2018 | 16187290 | 88196000 |
| Tuesday, January 1, 2019 | 9299233.54 | 89971000 |
| Wednesday, January 1, 2020 | 19232000 | 93413000 |
| Friday, January 1, 2021 | 23611000 | 91355000 |
| Saturday, January 1, 2022 | 26700000 | 113676000 |
| Sunday, January 1, 2023 | 28215000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. Summit Therapeutics Inc. and Taro Pharmaceutical Industries Ltd. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Summit Therapeutics saw a steady increase in SG&A expenses, peaking in 2023 with a 315% rise from 2014. Meanwhile, Taro Pharmaceutical's expenses remained relatively stable until a significant surge in 2023, marking a 116% increase from 2014. This divergence highlights Summit's aggressive expansion strategy, while Taro's recent spike suggests a shift in operational focus. Notably, data for Summit in 2024 is missing, indicating potential changes in reporting or strategy. These insights provide a window into the financial maneuvers of these companies, offering investors and analysts a deeper understanding of their market positioning.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Summit Therapeutics Inc.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Summit Therapeutics Inc.
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Summit Therapeutics Inc.
Neurocrine Biosciences, Inc. and Summit Therapeutics Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights
Summit Therapeutics Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Dr. Reddy's Laboratories Limited and Taro Pharmaceutical Industries Ltd.
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Selling, General, and Administrative Costs: Ultragenyx Pharmaceutical Inc. vs Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: Veracyte, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights